2m 2m 2m 2m 2m 2m 2m
Halozyme Therape (HALO)
NASDAQ
$113.00+$0.55 (+0.49%)
Price as of Sep 18, 2026 7:56 PM EDT- $12.8BMarket Cap
- 44.52%1-Year Change
- BiotechnologyIndustry
Halozyme Therape (HALO)
$113.00+$0.55 (+0.49%)
HALO | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $112.45 | ||
Change | +$2.77 (+2.53%) | ||
Open | $109.72 | ||
High | $112.66 | ||
Low | $109.38 | ||
Previous Close | $109.68 | ||
Volume | 10,348,962 | ||
30-Day Average Volume | 1,923,845 | ||
1-Week Change | 4.90% | ||
1-Month Change | 7.21% | ||
1-Year Change | 44.52% | ||
3-Year Change | 187.52% | ||
5-Year Change | 167.48% | ||
Fundamentals | |||
Shares Outstanding | 113.5M | ||
Total Assets | $2.6B | ||
Market Cap | $12.8B | ||
Enterprise Value | $14.7B | ||
Period: QTR TTM FY | |||
Revenue | $307.7M | ||
Net Income | $229.9M | ||
Free Cash Flow | $236.7M | ||
EBIT | $285.3M | ||
EBITDA | $314.8M | ||
Net Working Capital | $588.6M | ||
EPS | $1.90 | ||
Enterprise Value/EBITDA | 47 | ||
Enterprise Value/Revenue | 48 | ||
P/B | 89 | ||
P/E | 59 | ||
PEG | 1 | ||
Price/Free Cash Flow | 54 | ||
Price/Operating Cash Flow | 53 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue